Skip to content
← Catalog

Kelonia Therapeutics · KLN-1010 (per ASGCT 2025 abstracts)

Kelonia Therapeutics · in vivo cell therapy 公司 · KLN-1010 是主要 pipeline candidate(per OPORD-002 §2 P1 verify list · ASGCT 2025 abstracts)。 对 SunVax 的对标:in vivo cell engineering 大方向 · 具体 modality 待 verify。

Type
company
Domain
conference
Grade
conference
License
LIGHT_HOPE_proprietary
evidence_grade
B
category
in_vivo_car_t_lentiviral
status
draft
instance_tag
sunvax-antibody-2025
platform_tech
in vivo cell therapy (modality TBD)

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.